Chi­na's mar­ket reg­u­la­tor fines, con­fis­cates rev­enue from phar­mas for mo­nop­o­liz­ing APIs for ep­i­neph­rine

Chi­na’s mar­ket reg­u­la­tor, the State Ad­min­is­tra­tion for Mar­ket Reg­u­la­tion, an­nounced on Sun­day that it fined and con­fis­cat­ed rev­enue from two phar­ma com­pa­nies for what it called a mo­nop­o­lis­tic deal.

Grand Phar­ma­ceu­ti­cal was fined $19.68 mil­lion (139.3 mil­lion yuan) and the reg­u­la­tor con­fis­cat­ed $21 mil­lion (149 mil­lion yuan) of what it called “il­le­gal rev­enue” for en­ter­ing in­to a mo­nop­oly with Wuhan Heal­care Phar­ma­ceu­ti­cals over two drugs and their ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs): nor­ep­i­neph­rine bitar­trate and ep­i­neph­rine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER